Cite
MLA Citation
Robert Pirker and Martin Filipits. “From crizotinib to lorlatinib: continuous improvement in precision treatment of ALK-positive non-small cell lung cancer.” ESMO open, vol. 4, no. 5, 2019, p. . http://access.bl.uk/ark:/81055/vdc_100127572798.0x00001d